HomeCompareENTOF vs ABBV

ENTOF vs ABBV: Dividend Comparison 2026

ENTOF yields 2.06% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTOF wins by $72.60M in total portfolio value· pulled ahead in Year 4
10 years
ENTOF
ENTOF
● Live price
2.06%
Share price
$11.17
Annual div
$0.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$72.70M
Annual income
$66,495,488.82
Full ENTOF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ENTOF vs ABBV

📍 ENTOF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTOF
Annual income on $10K today (after 15% tax)
$174.99/yr
After 10yr DRIP, annual income (after tax)
$56,521,165.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ENTOF beats the other by $56,500,109.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTOF + ABBV for your $10,000?

ENTOF: 50%ABBV: 50%
100% ABBV50/50100% ENTOF
Portfolio after 10yr
$36.40M
Annual income
$33,260,130.29/yr
Blended yield
91.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ENTOF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
0.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTOF buys
0
ABBV buys
0
No recent congressional trades found for ENTOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTOFABBV
Forward yield2.06%3.06%
Annual dividend / share$0.23$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$72.70M$102.3K
Annual income after 10y$66,495,488.82$24,771.77
Total dividends collected$72.20M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ENTOF vs ABBV ($10,000, DRIP)

YearENTOF PortfolioENTOF Income/yrABBV PortfolioABBV Income/yrGap
1$11,112$411.73$11,550$430.00$438.00ABBV
2$12,745$855.15$13,472$627.96$727.00ABBV
3$15,470$1,833.32$15,906$926.08$436.00ABBV
4← crossover$20,713$4,159.57$19,071$1,382.55+$1.6KENTOF
5$32,572$10,409.63$23,302$2,095.81+$9.3KENTOF
6$65,450$30,597.98$29,150$3,237.93+$36.3KENTOF
7$184,954$114,922.06$37,536$5,121.41+$147.4KENTOF
8$804,919$607,018.49$50,079$8,338.38+$754.8KENTOF
9$5,799,105$4,937,841.75$69,753$14,065.80+$5.73MENTOF
10$72,700,531$66,495,488.82$102,337$24,771.77+$72.60MENTOF

ENTOF vs ABBV: Complete Analysis 2026

ENTOFStock

Entra ASA owns, develops, leases, and manages office properties in Norway. As of December 31, 2021, it had a property portfolio of 96 properties with a total area of approximately 1.5 million square meters. The company was founded in 2000 and is headquartered in Oslo, Norway.

Full ENTOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ENTOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTOF vs SCHDENTOF vs JEPIENTOF vs OENTOF vs KOENTOF vs MAINENTOF vs JNJENTOF vs MRKENTOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.